Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Imprimer Veuillez voter Vote 1 Vote 2 Vote 3 Vote 4 Vote 5 Author: Read Full Article
